|
R. Wayne Rundles made substantial contributions to cancer research and was a leader in the development of national cancer programs and policies.
Dr. Rundles first became interested in science while completing a fellowship at DePauw University in 1928 and subsequently received his medical degree from Duke University in 1940. Dr. Rundles served as director of the hematology and chemotherapy service at Duke University Hospital and eventually became chief of hematology/oncology.
Dr. Rundles played an active role in the American Cancer Society as well as ASH. He served as president of ASH in 1967.
We encourage you to honor Dr. Rundles by sharing your thoughts or stories through the Legends in Hematology Guestbook or by making a special gift to ASH.
|
|
Dr. Rundles was one of the first major hematologists to take a lead in medical oncology. He made significant contributions to treatment of patients with multiple myeloma, acute and chronic myelogenous leukemia, chronic lymphocytic leukemia, discovery of allopurinol and Immuran (in collaboration with Hitchings and Elion and several colleagues at Duke) and in new drug discovery for hematologic malignancies, gout and immune suppression.
– John Laszlo, MD
I had the opportunity to know and work with Dr. Rundles at Duke University, first as a house officer -- later, after fellowship training in cardiology at Duke, and hematology/clinical pathology at the NIH, as a junior faculty member. I respected his intellect greatly, did not always see eye-to-eye with him on clinical and administrative matters, but learned a great deal from him and mourned his passing. I value highly this window into his history and his dispassionate (and humorous) assessment of his colleagues and his own many contributions to hematology and medicine. Thank you.
– Judith C. Andersen, MD |
